Published in Int J Exp Pathol on February 12, 2011
Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46
Redirecting valvular myofibroblasts into dormant fibroblasts through light-mediated reduction in substrate modulus. PLoS One (2012) 1.41
miRNAs in the vitreous humor of patients affected by idiopathic epiretinal membrane and macular hole. PLoS One (2017) 1.39
Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther (2011) 1.31
Role of MicroRNAs in Fibrosis. Open Rheumatol J (2012) 1.14
cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol (2012) 1.04
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One (2012) 0.95
What is the best way to measure renal fibrosis?: A pathologist's perspective. Kidney Int Suppl (2011) (2014) 0.90
Gene expression profiles reveal molecular mechanisms involved in the progression and resolution of bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 0.88
Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair (2012) 0.88
Stem cells: potential and challenges for kidney repair. Am J Physiol Renal Physiol (2013) 0.88
Resident mesenchymal cells and fibrosis. Biochim Biophys Acta (2012) 0.87
Bmi-1 plays a critical role in protection from renal tubulointerstitial injury by maintaining redox balance. Aging Cell (2014) 0.87
The roles of microRNAs on tuberculosis infection: meaning or myth? Tuberculosis (Edinb) (2013) 0.86
Myofibroblast persistence with real-time changes in boundary stiffness. Acta Biomater (2015) 0.77
Experimental models of renal disease. Int J Exp Pathol (2011) 0.75
Benefical therapeutic effect of Chinese Herbal Xinji'erkang formula on hypertension-induced renal injury in the 2-kidney-1-clip hypertensive rats. Afr J Tradit Complement Altern Med (2014) 0.75
miR302 regulates SNAI1 expression to control mesangial cell plasticity. Sci Rep (2017) 0.75
Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 12.56
Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest (2002) 12.22
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol (2009) 7.34
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest (2007) 6.56
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83
Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol (2004) 5.43
Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol (2008) 5.06
Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol (2005) 4.35
ECM remodeling in hypertensive heart disease. J Clin Invest (2007) 4.03
Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57
Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res (2002) 2.22
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 2.16
Structural development of endocardial cushions. Am J Anat (1977) 2.07
Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol (2009) 2.01
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes (2007) 1.94
HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int (2006) 1.85
Toward a unified theory of renal progression. Annu Rev Med (2006) 1.81
Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev (1999) 1.72
Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci (1992) 1.65
Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am J Pathol (2005) 1.64
The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs (2007) 1.46
Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol (2003) 1.40
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 1.39
Stem cell options for kidney disease. J Pathol (2009) 1.38
Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol (2006) 1.37
Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol (2004) 1.29
Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens (2006) 1.26
Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol (2008) 1.17
Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium (2005) 1.15
Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS One (2009) 1.14
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J (2004) 1.13
The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl (2000) 1.10
Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl (2003) 1.06
Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation (1999) 1.06
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol (2009) 1.05
The origin of renal fibroblasts and progression of kidney disease. Am J Pathol (2009) 1.05
Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol (2003) 1.05
Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension (2000) 1.04
Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int (2006) 1.02
Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. J Pathol (2007) 1.01
Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol (2001) 1.01
Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest (1998) 0.97
Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension (2001) 0.95
Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol (1999) 0.94
Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis (1998) 0.93
Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J (2002) 0.93
Mesangial AT1 receptors: expression, signaling, and regulation. J Am Soc Nephrol (1999) 0.92
Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant (1996) 0.90
Renal fibrosis and the renin-angiotensin system. Adv Nephrol Necker Hosp (2001) 0.83
AT1 receptor expression in glomeruli from NO-deficient rats. Nephron Exp Nephrol (2003) 0.76
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2008) 3.66
Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol (2008) 2.60
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 2.16
Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) (2009) 1.81
Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. J Am Soc Nephrol (2009) 1.77
Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol (2012) 1.69
Acute renal infarction: a case series. Clin J Am Soc Nephrol (2012) 1.68
Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. J Pathol (2012) 1.63
Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. Respir Med (2012) 1.61
IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) (2012) 1.54
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol (2012) 1.42
Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol (2008) 1.38
Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension (2007) 1.36
Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis (2011) 1.23
Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res (2008) 1.18
Renal arterial resistive index is associated with severe histological changes and poor renal outcome during chronic kidney disease. BMC Nephrol (2012) 1.16
Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS One (2009) 1.14
Renal involvement in Castleman disease. Nephrol Dial Transplant (2010) 1.13
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J (2004) 1.13
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int (2008) 1.08
Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol (2006) 1.08
SOX9 exerts a bifunctional effect on type II collagen gene (COL2A1) expression in chondrocytes depending on the differentiation state. DNA Cell Biol (2003) 1.05
Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.05
Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol (2008) 1.04
Early postnatal nutrition determines somatotropic function in mice. Endocrinology (2008) 1.04
Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol (2011) 1.03
Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol (2011) 1.02
A case of phospholipase A₂ receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis (2010) 1.01
Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis (2011) 1.00
Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis. FASEB J (2012) 0.99
Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol (2004) 0.99
Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol (2010) 0.97
Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol (2007) 0.97
Williams-Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in calcium homeostasis? Pediatrics (2012) 0.95
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One (2012) 0.95
Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J (2002) 0.93
Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors. J Biol Chem (2007) 0.93
Alteration of connexin expression is an early signal for chronic kidney disease. Am J Physiol Renal Physiol (2011) 0.92
Notch3 is essential for regulation of the renal vascular tone. Hypertension (2011) 0.91
GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly. Am J Kidney Dis (2012) 0.90
Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int (2012) 0.89
Nephroangiosclerosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: is NOTCH3 mutation the common culprit? Am J Kidney Dis (2008) 0.89
Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Chest (2005) 0.88
Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant (2005) 0.88
Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab (2013) 0.87
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension (2012) 0.86
Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant (2010) 0.86
Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension (2003) 0.83
Sox9/Sox6 and Sp1 are involved in the insulin-like growth factor-I-mediated upregulation of human type II collagen gene expression in articular chondrocytes. J Mol Med (Berl) (2012) 0.83
The RenTg mice: a powerful tool to study renin-dependent chronic kidney disease. PLoS One (2012) 0.83
Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Hypertension (2013) 0.82
Performance of GFR estimating equations in African Europeans: basis for a lower race-ethnicity factor than in African Americans. Am J Kidney Dis (2013) 0.81
Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet J Rare Dis (2013) 0.80
Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney Int (2016) 0.80
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PLoS One (2012) 0.80
Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am J Physiol Renal Physiol (2009) 0.80
Transgelin Up-Regulation in Obstructive Nephropathy. PLoS One (2013) 0.79
Membranoproliferative glomerulonephritis, chronic lymphocytic leukemia, and cryoglobulinemia. Am J Kidney Dis (2009) 0.79
Acute renal failure associated with immune restoration inflammatory syndrome. Nat Clin Pract Nephrol (2006) 0.79
Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep (2013) 0.79
[Chronic kidney disease, new therapeutic approaches]. Rev Prat (2012) 0.78
c-Krox down-regulates the expression of UDP-glucose dehydrogenase in chondrocytes. Biochem Biophys Res Commun (2005) 0.78
Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Expert Opin Drug Discov (2014) 0.78
Video-thoracoscopic and open surgical management of thoracic empyema. Surg Infect (Larchmt) (2007) 0.78
Chondroitin sulphate decreases collagen synthesis in normal and scleroderma fibroblasts through a Smad-independent TGF-beta pathway--implication of C-Krox and Sp1. J Cell Mol Med (2008) 0.77
Losartan increases NO release in afferent arterioles during regression of L-NAME-induced renal damage. Am J Physiol Renal Physiol (2010) 0.77
Thorough clinical investigation of low cardiac output syndrome after subxiphoid pericardiostomy. Angiology (2007) 0.77
Diabetic CVD--soluble epoxide hydrolase as a target. Cardiovasc Hematol Agents Med Chem (2012) 0.76
Connexins in renal endothelial function and dysfunction. Cardiovasc Hematol Disord Drug Targets (2014) 0.76
Monitoring of hemodialysis quality-of-care indicators: why is it important? BMC Nephrol (2013) 0.75
Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults: A national retrospective strobe-compliant study. Medicine (Baltimore) (2016) 0.75
Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases. Medicine (Baltimore) (2015) 0.75
Light chain deposition disease and proximal tubulopathy in two successive kidney allografts. Clin Nephrol (2015) 0.75
[IgG4-related disease and renal and urological involvement]. Nephrol Ther (2012) 0.75
Differential circadian pattern of water and Na excretion rates in the metabolic syndrome. Chronobiol Int (2014) 0.75
[Vasoactive peptides and the development of renal sclerosis: contribution of transgenes]. J Soc Biol (2002) 0.75
[Role of cell plasticity in progression and regression of renal fibrosis]. Bull Acad Natl Med (2009) 0.75
[Reversal of renal fibrosis: lessons from experimental models]. Bull Acad Natl Med (2008) 0.75
The Role of Discoidin Domain Receptor 1 in Inflammation, Fibrosis and Renal Disease. Nephron (2017) 0.75
Editorial: renal endothelial dysfunction: evolving concepts and perspectives. Cardiovasc Hematol Disord Drug Targets (2014) 0.75
The Use of Ferritin to Identify Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis. Crit Care Med (2016) 0.75